Profluent raised $106 million in a financing led by Altimeter Capital and Bezos Expeditions to expand its large‑scale AI models for protein design. The Emeryville company will use the funds to accelerate R&D and commercial partnerships across therapeutics, agriculture and biomanufacturing. Profluent said its Protein Atlas now includes more than 115 billion proteins and that partners are already deploying its platform for enzymes, antibodies and other modalities. The company highlighted collaborations with Integrated DNA Technologies and Revvity to translate in‑silico designs to wet‑lab products. Investors framed the round as part of a broader surge of capital into AI‑driven biotech companies that aim to compress design timelines and reduce costs in biologics discovery.